<DOC>
	<DOCNO>NCT03059381</DOCNO>
	<brief_summary>The objective study identify follow adolescent epilepsy participant partial-onset seizure ( without secondary generalized seizure ) primary generalize Tonic-clonic seizure receive long-term treatment Fycompa : 1. unknown adverse drug reaction ( ADRs ) ; 2. occurrence ADRs ; 3. factor likely affect safety efficacy ; 4. occurrence dizziness , balance disorder , ataxia , muscle relaxation-related adverse event , fall priority investigation item ; 5. occurrence psychiatric adverse event priority investigation item ( eg , aggression ) .</brief_summary>
	<brief_title>Investigation Clinical Safety Efficacy Long-term Treatment With Fycompa Tablets Adolescence Epilepsy Patients With Partial-onset Seizures ( With Without Secondary Generalized Seizures ) Primary Generalized Tonic-clonic Seizures</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Epilepsy participant 12 17 year age : Partial seizure ( without secondary generalized seizure ) Primary generalize Tonicclonic seizure Participants previously treat Fycompa</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adolescent epilepsy participant</keyword>
	<keyword>partial seizure</keyword>
	<keyword>primary generalize Tonic-clonic seizure</keyword>
</DOC>